Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
14 pending office actions • 10 art units • 14 examiners • 0 of 14 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
University of Ulsan Foundation for Industry Cooperation has 15 pending office actions in the Medical Devices & Mechanical Engineering technology area. These 15 pending office actions are assigned to 15 distinct examiners, meaning there is no examiner overlap among the current pending matters. This creates a fragmented prosecution environment where the 15 pending office actions must be managed as unique interactions with 15 different officials.
The prosecution is spread across 11 distinct art units, showing technical range within the Medical Devices & Mechanical Engineering fields. ESAW T ABRAHAM is the busiest examiner for the foundation, with 1 pending office action. With 15 pending office actions and 15 distinct examiners, the foundation faces a diverse set of examiner relationships across 11 distinct art units. For practitioners, this fragmentation requires a management system to ensure that 15 different examiner styles and 11 distinct art unit standards are all addressed without personnel overlap.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (7%) |
| §103 only | 8 (57%) |
| §112 only | 1 (7%) |
| Multi-statute (no §101) | 4 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ABRAHAM, ESAW T | 1 | 94.2% | +3.2% |
| RAYMOND, LINNAE ELIZABETH | 1 | 48.8% | +55.5% |
| GEBREMICHAEL, BRUK A | 1 | 22.1% | +23.4% |
| JAHAN, ISRAT | 1 | — | — |
| PAK, YONG D | 1 | 74.6% | +14.3% |
| TRAN, JENNY NGAN | 1 | 44.4% | +33.3% |
| JOHNSON, NICOLE F | 1 | 87.4% | +7.0% |
| SLIFKA, SARAH A | 1 | 75.5% | +11.2% |
| LALISSE, REMY FREDERIC | 1 | 75.0% | +0.0% |
| PAULUS, ERIN VIRGINIA | 1 | 21.1% | +93.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18564790 | CATHETER APPARATUS FOR PHOTODYNAMIC THERAPY | JOHNSON, NICOLE F | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18352493 | ARTIFICIAL BLOOD VESSEL COMPLEX | WILLSE, DAVID H | 14d |
| 18262341 | STEM CELL IN WHICH IMMUNE CELL TOLERANCE MODULATOR IS OVEREXPRESSED, AND USE THEREOF | PAULUS, ERIN VIRGINIA | 20d |
| 19090293 | METHOD AND DEVICE FOR DECODING ERROR CORRECTING CODE | ABRAHAM, ESAW T | — |
| 18856351 | ARTIFICIAL STRUCTURE FOR PREVENTING OR TREATING LYMPHEDEMA AND CONSTRUCTION METHOD THEREFOR | RAYMOND, LINNAE ELIZABETH | — |
| 18757751 | APPARATUS AND METHOD FOR PROVIDING STEREOSCOPIC VISION TRAINING | GEBREMICHAEL, BRUK A | — |
| 18287891 | SULFIDE-BASED SOLID ELECTROLYTE, PREPARATION METHOD THEREOF, AND ALL-SOLID STATE BATTERY PREPARED THEREFROM | SLIFKA, SARAH A | — |
| 18285669 | NOVEL SUPRAMOLECULAR SELF-ASSEMBLY, CARBON NITRIDE AND PHOTOCATALYST USING SAME, AND MANUFACTURING METHOD THEREFOR | LALISSE, REMY FREDERIC | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18262341 | STEM CELL IN WHICH IMMUNE CELL TOLERANCE MODULATOR IS OVEREXPRESSED, AND USE THEREOF | PAULUS, ERIN VIRGINIA | 20d |
| 18856351 | ARTIFICIAL STRUCTURE FOR PREVENTING OR TREATING LYMPHEDEMA AND CONSTRUCTION METHOD THEREFOR | RAYMOND, LINNAE ELIZABETH | — |
| 18757751 | APPARATUS AND METHOD FOR PROVIDING STEREOSCOPIC VISION TRAINING | GEBREMICHAEL, BRUK A | — |
| 18707174 | SORD AS BIOMARKER FOR PREDICTING PROGNOSIS AFTER LIVER CANCER SURGERY | PAK, YONG D | — |
| 18681973 | TYMPANUM IMAGE PROCESSING APPARATUS AND METHOD FOR GENERATING NORMAL TYMPANUM IMAGE BY USING MACHINE LEARNING MODEL TO OTITIS MEDIA TYMPANUM IMAGE | TRAN, JENNY NGAN | — |
| 18287891 | SULFIDE-BASED SOLID ELECTROLYTE, PREPARATION METHOD THEREOF, AND ALL-SOLID STATE BATTERY PREPARED THEREFROM | SLIFKA, SARAH A | — |
| Art Unit | Apps |
|---|---|
| 3792 | 1 |
| 1645 | 1 |
| 2615 | 1 |
| 3796 | 1 |
| 1742 | 1 |
| 1631 | 1 |
| 3774 | 1 |
| 2817 | 1 |
| 3781 | 1 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19090293 | METHOD AND DEVICE FOR DECODING ERROR CORRECTING CODE | ABRAHAM, ESAW T | — | §101§103 | Non-Final OA | — | Pending | Mar 25, 2025 |
| 18856351 | ARTIFICIAL STRUCTURE FOR PREVENTING OR TREATING LYMPHEDEMA AND CONSTRUCTION METHOD THEREFOR | RAYMOND, LINNAE ELIZABETH | — | §103§112 | Non-Final OA | — | Pending | Oct 11, 2024 |
| 18757751 | APPARATUS AND METHOD FOR PROVIDING STEREOSCOPIC VISION TRAINING | GEBREMICHAEL, BRUK A | — | §103 | Non-Final OA | — | Pending | Jun 28, 2024 |
| 18556360 | LOW-LEVEL LASER THERAPY DEVICE USING LED ENDOSCOPE CAP | JAHAN, ISRAT | 3792 | §103 | Final Rejection | — | Pending | Jun 10, 2024 |
| 18707174 | SORD AS BIOMARKER FOR PREDICTING PROGNOSIS AFTER LIVER CANCER SURGERY | PAK, YONG D | 1645 | §112 | Non-Final OA | — | Pending | May 03, 2024 |
| 18681973 | TYMPANUM IMAGE PROCESSING APPARATUS AND METHOD FOR GENERATING NORMAL TYMPANUM IMAGE BY USING MACHINE LEARNING MODEL TO OTITIS MEDIA TYMPANUM IMAGE | TRAN, JENNY NGAN | 2615 | §103 | Final Rejection | — | Pending | Feb 07, 2024 |
| 18564790 | CATHETER APPARATUS FOR PHOTODYNAMIC THERAPY | JOHNSON, NICOLE F | 3796 | §103 | Final Rejection | — | Pending | Nov 28, 2023 |
| 18287891 | SULFIDE-BASED SOLID ELECTROLYTE, PREPARATION METHOD THEREOF, AND ALL-SOLID STATE BATTERY PREPARED THEREFROM | SLIFKA, SARAH A | — | §102§103§112 | Non-Final OA | — | Pending | Oct 23, 2023 |
| 18285669 | NOVEL SUPRAMOLECULAR SELF-ASSEMBLY, CARBON NITRIDE AND PHOTOCATALYST USING SAME, AND MANUFACTURING METHOD THEREFOR | LALISSE, REMY FREDERIC | 1742 | §102§103 | Non-Final OA | — | Pending | Oct 05, 2023 |
| 18262341 | STEM CELL IN WHICH IMMUNE CELL TOLERANCE MODULATOR IS OVEREXPRESSED, AND USE THEREOF | PAULUS, ERIN VIRGINIA | 1631 | §103 | Final Rejection | 20d | Pending | Jul 20, 2023 |
| 18352493 | ARTIFICIAL BLOOD VESSEL COMPLEX | WILLSE, DAVID H | 3774 | §102§103 | Final Rejection | 14d | Pending | Jul 14, 2023 |
| 18058956 | NANOSTRUCTURE-BASED SUBSTRATE FOR SURFACE-ENHANCED RAMAN SPECTROSCOPY, AND MANUFACTURING METHOD THEREFOR | LEE, DA WEI | 2817 | §103 | Final Rejection | 4d overdue | Pending | Nov 28, 2022 |
| 18056766 | RECTUM EXPANDING BALLOON CATHETER | NGO, MEAGAN N | 3781 | §103 | Non-Final OA | 14d | Pending | Nov 18, 2022 |
| 17995024 | STABILIZER FOR RADIOPHARMACEUTICALS AND RADIOPHARMACEUTICAL COMPOSITION COMPRISING THE SAME | MEJIAS, SAMANTHA LEE | 1618 | §103 | Final Rejection | 56d | Pending | Sep 29, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial